Inhibition of Phenylhydrazine-induced Hematotoxicity by Bioconverted Ginsenosides
Yuseong Chung1, Kang Min Kim2★, Jae Seon Kang1★★ Corresponding author
- 1Department of Pharmacy, Kyungsung University, Busan, REPUBLIC OF KOREA.
- 2Department of Pharmaceutical Science and Technology, Kyungsung University, Busan, REPUBLIC OF KOREA.
CORRESPONDENCE
Kang Min Kim
Department of Pharmaceutical Science and Technology, Kyungsung University, Busan, REPUBLIC OF KOREA.
Received: 17-03-2022; Revised: 05-04-2023; Accepted: 16-06-2023.
Volume 57, Issue 4 · pp. 1132–1139 · PUBLISHED 2023 · DOI: 10.5530/ijper.57.4.136
ABSTRACT
Aim: To identify the inhibition of Phenylhydrazine (PHZ)-induced hepatotoxicity and anemia by bioconverted ginsenosides. Materials and Methods: We examined the potential benefits of bioconverted ginsenosides on anemia in a phenylhydrazine-induced rat model and described the prolonging effect of erythrocyte life span by focusing on compound K that was confirmed through ex vivo experiments. Results: Hematological analysis demonstrated that all groups treated with bioconverted ginsenosides showed significant recovery results. In the ex vivo experiments, compound K was treated in stored blood, and the erythrocytes half-life was 45 days, 15 days longer than when not treated in blood. In the ICP-OES assay, PHZ-induced erythrocyte hemolysis was significantly inhibited by bioconverted ginsenosides. Conclusion: Based on the present results, it has been demonstrated that bioconverted ginsenoside aids in prolonging the erythrocyte life span and increasing erythrocyte count in vivo. Thus, this material has the potential to develop as a promising drug candidate in the future.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Chung, Y., Kim, K. M., & Kang, J. S. (2023). Inhibition of Phenylhydrazine-induced Hematotoxicity by Bioconverted Ginsenosides. Indian Journal of Pharmaceutical Education and Research, 57(4), 1132–1139. https://doi.org/10.5530/ijper.57.4.136
